MaxCyte（MXCT）株式概要ライフサイエンス企業であるMaxCyte, Inc.は、細胞治療薬の発見、開発、商業化を米国内外で行っている。 詳細MXCT ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長1/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間18.31%増加すると予測されています リスク分析現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るMXCT Community Fair Values Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN81.9% undervaluedAnalystConsensusTarget•5mo agoUpcoming Cell And Gene Therapy Milestones Are Expected To Transform Long Term Royalty Prospects2901AN86.6% undervaluedAnalystHighTarget•5mo agoCell And Gene Therapy Tailwinds Will Drive Meaningful Long Term Upside Potential300AN75.8% undervaluedAnalystLowTarget•4mo agoGene Editing Royalties And Slow Adoption Will Pressure Results Yet Support Long Term Upside1000Top Analyst NarrativesAN81.9% undervaluedAnalystConsensusTarget•5mo agoUpcoming Cell And Gene Therapy Milestones Are Expected To Transform Long Term Royalty Prospects2901AN86.6% undervaluedAnalystHighTarget•5mo agoCell And Gene Therapy Tailwinds Will Drive Meaningful Long Term Upside Potential300AN75.8% undervaluedAnalystLowTarget•4mo agoGene Editing Royalties And Slow Adoption Will Pressure Results Yet Support Long Term Upside1000View all narrativesMaxCyte, Inc. 競合他社Atlantic InternationalSymbol: NasdaqGM:ATLNMarket cap: US$119.0mSeerSymbol: NasdaqGS:SEERMarket cap: US$105.5mQuanterixSymbol: NasdaqGM:QTRXMarket cap: US$144.1mMindWalk HoldingsSymbol: NasdaqCM:HYFTMarket cap: US$87.4m価格と性能株価の高値、安値、推移の概要MaxCyte過去の株価現在の株価US$1.2152週高値US$2.4052週安値US$0.64ベータ1.571ヶ月の変化37.50%3ヶ月変化53.53%1年変化-49.16%3年間の変化-72.31%5年間の変化n/aIPOからの変化-25.77%最新ニュースお知らせ • May 14MaxCyte, Inc. Reiterates Earnings Revenue Guidance for the Full Year 2026MaxCyte, Inc. reiterated earnings revenue guidance for the full year 2026. For the full year, the company revenue expected to be $30 million to $32 million.お知らせ • May 13MaxCyte, Inc. (NasdaqGS:MXCT) announces an Equity Buyback for $10 million worth of its shares.MaxCyte, Inc. (NasdaqGS:MXCT) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of its common stock. The program is valid for 1 year.お知らせ • May 03MaxCyte, Inc., Annual General Meeting, Jun 17, 2026MaxCyte, Inc., Annual General Meeting, Jun 17, 2026. Location: 9713 key west avenue, suite 400, md 20850, rockville United Statesお知らせ • Apr 30MaxCyte, Inc. to Report Q1, 2026 Results on May 12, 2026MaxCyte, Inc. announced that they will report Q1, 2026 results After-Market on May 12, 2026お知らせ • Mar 25+ 1 more updateMaxCyte, Inc. Provides Earnings Guidance for the Full Year 2026MaxCyte, Inc. provided earnings guidance for the full year 2026. For the full year, the company expects revenue expected to be $30 million to $32 million.お知らせ • Mar 23MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026MaxCyte, Inc. announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization, most recently serving as Vice President, Investor Relations at Agilent Technologies, where he worked closely with senior leadership to help shape and communicate the company’s narrative to analysts and investors. Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations. Mr. Ahuja holds an MBA in Finance from San Jose State University and a Bachelor of Commerce in Accounting from Delhi University.最新情報をもっと見るRecent updatesお知らせ • May 14MaxCyte, Inc. Reiterates Earnings Revenue Guidance for the Full Year 2026MaxCyte, Inc. reiterated earnings revenue guidance for the full year 2026. For the full year, the company revenue expected to be $30 million to $32 million.お知らせ • May 13MaxCyte, Inc. (NasdaqGS:MXCT) announces an Equity Buyback for $10 million worth of its shares.MaxCyte, Inc. (NasdaqGS:MXCT) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of its common stock. The program is valid for 1 year.お知らせ • May 03MaxCyte, Inc., Annual General Meeting, Jun 17, 2026MaxCyte, Inc., Annual General Meeting, Jun 17, 2026. Location: 9713 key west avenue, suite 400, md 20850, rockville United Statesお知らせ • Apr 30MaxCyte, Inc. to Report Q1, 2026 Results on May 12, 2026MaxCyte, Inc. announced that they will report Q1, 2026 results After-Market on May 12, 2026お知らせ • Mar 25+ 1 more updateMaxCyte, Inc. Provides Earnings Guidance for the Full Year 2026MaxCyte, Inc. provided earnings guidance for the full year 2026. For the full year, the company expects revenue expected to be $30 million to $32 million.お知らせ • Mar 23MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026MaxCyte, Inc. announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization, most recently serving as Vice President, Investor Relations at Agilent Technologies, where he worked closely with senior leadership to help shape and communicate the company’s narrative to analysts and investors. Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations. Mr. Ahuja holds an MBA in Finance from San Jose State University and a Bachelor of Commerce in Accounting from Delhi University.お知らせ • Mar 21MaxCyte, Inc. Announces Notice of Non-Compliance with Nasdaq Minimum Bid Price RequirementOn March 16, 2026, MaxCyte, Inc. received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Select Market, and the Company's common stock will continue to trade on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until September 14, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive trading days prior September 14, 2026. If the Company does not regain compliance by September 14, 2026, the Company may be eligible for an additional 180 calendar day compliance period if it applies to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period. As part of its review process, Nasdaq will make a determination as to whether it believes the Company will be able to cure this deficiency. If Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company's common stock will be subject to delisting. Upon receipt of such notice, the Company would have the right to appeal any determination to delist its common stock, and the common stock would remain listed on the Nasdaq Global Select Market until completion of the appeal process. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other applicable Nasdaq listing rules.お知らせ • Feb 24+ 1 more updateMaxCyte, Inc. Unveils Expert DTx, A 96-Well Electroporation Platform to Accelerate DiscoveryMaxCyte, Inc. announced the launch of ExPERT DTx, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes. ExPERT DTx streamlines workflows by processing up to 96 samples in a single, three-minute run. The platform's R-50x96 well processing assembly provides one of the most cost-effective solutions for 96-well electroporation on the market, allowing 12 detachable 8-well strips to be processed in parallel with unique parameters for different cell and cargo combinations. This ensures consistent well-to-well performance that effectively eliminates transfection as an experimental variable, while maximizing flexibility and reducing laboratory waste. It has been validated in a range of applications - from cell and gene therapy development to protein production - and enables the transfer of optimized processes to other ExPERT instruments, simplifying scale-up from discovery into cGMP-compliant manufacturing without the need to reoptimize workflows. One of the defining features of the platform is its efficient and user-friendly software package. The DTx Software controls and monitors the instrument, while the DTx Designer software introduces a distinct advantage over current options on the market, enabling users to design their experiments remotely, then upload the workflow when the system is available for use. This maximizes uptime, and is especially beneficial to labs running multiple, back-to-back experiments.お知らせ • Nov 13MaxCyte, Inc. Announces Planned CFO Transition in 2026MaxCyte, Inc. announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working closely to ensure a smooth and orderly transition, and he will remain Chief Financial Officer until a successor has been appointed. The Company has initiated a structured search process to identify Mr. Swirsky’s successor. Following the transition period, Mr. Swirsky will continue in an advisory capacity to support strategic initiatives and ensure continuity.お知らせ • Nov 05MaxCyte, Inc. Reiterates Revenue Guidance for the Full Year 2025MaxCyte, Inc. reiterated revenue guidance for the full year 2025. The company core revenue is expected to be flat to a 10% decline compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.お知らせ • Oct 08MaxCyte, Inc. to Report Q3, 2025 Results on Nov 05, 2025MaxCyte, Inc. announced that they will report Q3, 2025 results After-Market on Nov 05, 2025お知らせ • Sep 23+ 1 more updateMaxCyte, Inc. Reiterates Earnings Guidance for the Year 2025MaxCyte, Inc. reiterated earnings guidance for the year 2025. Consistent with its previously issued outlook, The company is reiterating that 2025 core revenue is expected to be flat to down approximately 10% compared to 2024.お知らせ • Aug 07MaxCyte, Inc. Lowers Earnings Guidance for the Year 2025MaxCyte, Inc. lowered earnings guidance for the year 2025. For the year, Core revenue is expected to be flat to a 10% decline compared to 2024, inclusive of revenue from SeQure Dx.お知らせ • Jul 09MaxCyte, Inc. to Report Q2, 2025 Results on Aug 06, 2025MaxCyte, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025お知らせ • Jun 25MaxCyte Shareholders Approves Common Stock Cancelation DateMaxCyte, Inc. provided further update with regards to the cancellation of admission of the Company's common stock ("Common Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at the Annual General Meeting held on 18 June 2025. Shareholders are reminded that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025. Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.お知らせ • May 08MaxCyte, Inc. Reiterates Revenue Guidance for the Year 2025MaxCyte, Inc. reiterated revenue guidance for the year 2025. For the year, the company reiterates core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.お知らせ • Apr 17MaxCyte, Inc., Annual General Meeting, Jun 18, 2025MaxCyte, Inc., Annual General Meeting, Jun 18, 2025. Location: 9713 key west avenue, suite 400, rockville, 20850, maryland United Statesお知らせ • Apr 10MaxCyte, Inc. to Report Q1, 2025 Results on May 07, 2025MaxCyte, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025New Risk • Mar 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$46k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Significant insider selling over the past 3 months (US$46k sold).Seeking Alpha • Mar 15MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share PriceSummary MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by the strong growth of the global cell therapy market. Geopolitical tensions and a slowdown in the economy have hurt the share price, not problems in the company's business operations. MaxCyte's robust financial situation and strategic growth initiatives make its current share price attractive relative to its potential upside. Read the full article on Seeking AlphaReported Earnings • Mar 12Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.39 loss per share (further deteriorated from US$0.37 loss in FY 2023). Revenue: US$38.6m (down 6.4% from FY 2023). Net loss: US$41.1m (loss widened 8.3% from FY 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.1%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Mar 12MaxCyte, Inc. Provides Revenue Guidance for the Year 2025MaxCyte, Inc. provided revenue guidance for the year 2025. For the period, the company expects core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.Price Target Changed • Mar 09Price target decreased by 7.1% to US$8.67Down from US$9.33, the current price target is an average from 2 analysts. New target price is 147% above last closing price of US$3.51. Stock is down 11% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.37 last year.Buy Or Sell Opportunity • Feb 12Now 24% undervaluedOver the last 90 days, the stock has risen 17% to US$4.14. The fair value is estimated to be US$5.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.お知らせ • Feb 07MaxCyte, Inc. to Report Q4, 2024 Results on Mar 11, 2025MaxCyte, Inc. announced that they will report Q4, 2024 results at 4:30 PM, GMT Standard Time on Mar 11, 2025お知らせ • Jan 30MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million.MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million on January 30, 2025. Maxcyte paid a total consideration of $4.5 million at closing in cash for the entire issued share capital of SeQure DX on a cash free, debt free basis using Maxcyte’s existing cash resources and an additional amount of $2.5 million to be paid in contingent consideration if the SeQure exceeds certain revenue targets. For the period ending December 31, 2024, SeQure Dx, Inc. reported total revenue of $1.7 million and net loss of $6.5 million and total assets of $0.7 million. MaxCyte, Inc. (AIM:MXCT) completed the acquisition of SeQure Dx, Inc. on January 30, 2025.Buy Or Sell Opportunity • Jan 24Now 21% undervaluedOver the last 90 days, the stock has risen 31% to US$4.66. The fair value is estimated to be US$5.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.お知らせ • Dec 23MaxCyte, Inc. Announces Retirement of Board Member Art MandellMaxCyte, Inc. announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors. During Mr. Mandell’s tenure, MaxCyte has achieved significant milestones including its initial public offering on the UK AIM exchange and US Nasdaq Listing, the launch of its flagship ExPERT™ platform, signing 29 Strategic Platform Licenses with cell and gene therapy biotech companies and supporting the industry’s first, FDA-approved, CRISPR edited non-viral cell therapy.Price Target Changed • Dec 10Price target decreased by 7.1% to US$8.67Down from US$9.33, the current price target is an average from 2 analysts. New target price is 108% above last closing price of US$4.17. Stock is down 17% over the past year. The company is forecast to post a net loss per share of US$0.41 next year compared to a net loss per share of US$0.37 last year.お知らせ • Dec 10MaxCyte, Inc. Raises Revenue Guidance for 2024MaxCyte, Inc. raised Revenue guidance for 2024. For the period, the company expects core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.Reported Earnings • Nov 07Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.11 loss per share (further deteriorated from US$0.11 loss in 3Q 2023). Revenue: US$8.16m (up 2.0% from 3Q 2023). Net loss: US$11.6m (loss widened 2.7% from 3Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 07MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024MaxCyte, Inc. updated revenue guidance for the full year 2024. For the period, Company expects core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.お知らせ • Oct 15MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive DirectorMaxCyte, Inc. announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. Ms. Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as Chief Executive Officer of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene modified therapy. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc., Chief Executive Officer/General Manager of General Electric Healthcare's Cell Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy company. Currently, Ms. Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics, Certara, DermTech, Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines. Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business. Cynthia Collins, was previously appointed as an independent director to the Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the District of Delaware approved the sale of a substantial amount of DermTech Inc.'s assets through a court-supervised auction.お知らせ • Oct 11MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024MaxCyte, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024お知らせ • Oct 10MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial OfficerMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company’s market impact in Cell and Gene Therapy. Prior to his role as Chief Commercial Officer, Mr. Soleymannezhad was the Executive Vice President of Bioprocessing, where he led global product development and marketing strategy for MaxCyte’s bioprocessing business. Mr. Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to Executive Vice President of Bioprocessing at MaxCyte, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience and oversaw a team of 140 employees across four global manufacturing, development, and commercial sites. Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing-Americas at Tosoh and served on the board of Semba Biosciences.Reported Earnings • Aug 07Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.09 loss per share (improved from US$0.10 loss in 2Q 2023). Revenue: US$10.4m (up 15% from 2Q 2023). Net loss: US$9.38m (loss narrowed 11% from 2Q 2023). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 07MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. reaffirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance. The company continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$42m net loss in 2 years). Share price has been volatile over the past 3 months (9.8% average weekly change).お知らせ • Jul 10MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024MaxCyte, Inc. announced that they will report Q2, 2024 results at 4:30 PM, GMT Standard Time on Aug 06, 2024お知らせ • Jul 03MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth IndexMaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth IndexRecent Insider Transactions • Jun 13President recently bought US$489k worth of stockOn the 10th of June, Maher Masoud bought around 100k shares on-market at roughly US$4.89 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Maher's only on-market trade for the last 12 months.お知らせ • May 09Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. affirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and is increasing SPL Program-related revenue guidance. MaxCyte continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $5 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY™.Price Target Changed • May 08Price target decreased by 7.1% to US$8.67Down from US$9.33, the current price target is an average from 2 analysts. New target price is 87% above last closing price of US$4.64. Stock is down 0.2% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.37 last year.お知らせ • Apr 28MaxCyte, Inc., Annual General Meeting, Jun 11, 2024MaxCyte, Inc., Annual General Meeting, Jun 11, 2024, at 11:00 US Eastern Standard Time. Location: 9713 Key West Avenue, Suite 400 Rockville Maryland United States Agenda: To elect the Board’s three nominees as identified in the accompanying Proxy Statement as Class III directors: Will Brooke, John Johnston, and Richard Douglas; to approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the shares of the Company’s common stock issuable thereunder by 2,300,000 shares; to ratify the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.お知らせ • Apr 11MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024MaxCyte, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024お知らせ • Mar 14MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024MaxCyte, Inc. reiterated earnings guidance for the year 2024. Management is reiterating 2024 revenue guidance for core business revenue and SPL Program-related revenue. Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million. Outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM and reflects a difficult year-over-year comparison from a client milestone recognized in 2023 that was initially expected in 2024.Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.37 loss per share (further deteriorated from US$0.23 loss in FY 2022). Revenue: US$41.3m (down 6.7% from FY 2022). Net loss: US$37.9m (loss widened 61% from FY 2022). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.お知らせ • Mar 07MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024MaxCyte, Inc. provided revenue guidance for the fiscal year 2023 and 2024. For the year 2023, Company re-affirms total revenue to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022. Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.For the Year 2024, Company expects Core revenue to be flat to 5% growth compared to 2023.お知らせ • Feb 10MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024MaxCyte, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024お知らせ • Jan 27MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific OfficerMaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.’s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company’s Scientific Advisory Board.お知らせ • Jan 09MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023MaxCyte, Inc. provided preliminary financial guidance for the fourth quarter and full year ended December 31, 2023. Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.お知らせ • Dec 12MaxCyte, Inc. Provides Revenue Guidance Update for 2023MaxCyte, Inc. is reiterating 2023 expected core business revenue of $28 million- $30 million, and the company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million. Core business revenue consists of sales and leases of instrument and disposables to cell therapy and drug discovery customers and excludes any milestone revenues under SPL programs.New Risk • Nov 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$42m net loss in 2 years).お知らせ • Nov 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the period, the company expects total revenue to be approximately $34 million - 36 million.Reported Earnings • Nov 10Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.063 loss in 3Q 2022). Revenue: US$8.00m (down 25% from 3Q 2022). Net loss: US$11.3m (loss widened 75% from 3Q 2022). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 7.8%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Life Sciences industry in the US.お知らせ • Oct 07MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023MaxCyte, Inc. provided revenue guidance for the third quarter and full year of 2023. Total revenue of $7.8 million to $8.0 million in the third quarter of 2023, a decrease of 25% to 27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector.For the full year, the company’s total revenue now expected to be approximately $34 million to $36 million.New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.6% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$38m net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change).お知らせ • Oct 05MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023MaxCyte, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023Price Target Changed • Oct 05Price target decreased by 9.5% to US$9.50Down from US$10.50, the current price target is an average from 2 analysts. New target price is 191% above last closing price of US$3.27. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.23 last year.お知らせ • Sep 07Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. Mr. Soleymannezhad will lead global product development and marketing strategy for MaxCyte's bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and manufacturing using transient expression to produce complex proteins, vaccines and biologics at scale. Mr. Soleymannezhad brings almost 20 years of technical, sales and marketing expertise in biomanufacturing, bioprocessing and bioanalysis to his new role. Most recently, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience overseeing a team of 140 employees across four global manufacturing, development, and commercial sites. During his tenure at Tosoh, Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing Americas and served on the board of Semba Biosciences. Mr. Soleymannezhad received a Master of Business Administration in finance from Jones Graduate School of Business at Rice University in Texas after completing his Master and Bachelor of Chemical Engineering at University of Western Ontario's Faculty of Engineering in Canada.New Risk • Aug 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years).Price Target Changed • Aug 10Price target decreased by 9.5% to US$9.50Down from US$10.50, the current price target is an average from 2 analysts. New target price is 143% above last closing price of US$3.91. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.23 last year.お知らせ • Aug 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects core revenue to be comparable to 2022 and Strategic Platform License program-related revenue expectations remain unchanged at approximately $6 million.お知らせ • Jul 14MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023MaxCyte, Inc. announced that they will report Q2, 2023 results at 4:30 PM, GMT Standard Time on Aug 09, 2023Reported Earnings • May 12First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.04 loss in 1Q 2022). Revenue: US$8.58m (down 26% from 1Q 2022). Net loss: US$10.9m (loss widened 168% from 1Q 2022). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Life Sciences industry in the US.お知らせ • May 11MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects total revenue to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and Strategic Platform License (“SPL”) program-related revenue expectations remaining the same at approximately $6 million for the year.Board Change • Apr 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Member of Scientific Advisory Board Marcela Maus was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Apr 01Key Executive recently bought US$345k worth of stockOn the 29th of March, Richard Douglas bought around 80k shares on-market at roughly US$4.32 per share. This transaction increased Richard's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.Reported Earnings • Mar 16Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)Full year 2022 results: US$0.23 loss per share (further deteriorated from US$0.21 loss in FY 2021). Revenue: US$44.3m (up 31% from FY 2021). Net loss: US$23.6m (loss widened 24% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US.お知らせ • Feb 02MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023MaxCyte, Inc. announced that they will report Q4, 2022 results at 4:30 PM, GMT Standard Time on Mar 15, 2023Price Target Changed • Jan 08Price target decreased to US$11.67Down from US$13.67, the current price target is an average from 2 analysts. New target price is 123% above last closing price of US$5.23. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$0.25 next year compared to a net loss per share of US$0.21 last year.Reported Earnings • Nov 11Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.063 loss per share (further deteriorated from US$0.032 loss in 3Q 2021). Revenue: US$10.6m (up 5.0% from 3Q 2021). Net loss: US$6.43m (loss widened 140% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.Seeking Alpha • Sep 21MaxCyte expands capacity by relocating to new HQ in MarylandMaxCyte (NASDAQ:MXCT) said it relocated its headquarters to Key West Avenue in Rockville, Maryland, within Maryland's I-270 Biotech Corridor. The new 67K square-foot facility increases MaxCyte's in-house manufacturing capacity and research and process development lab space, the company said in a Sept. 21 press release. MXCT -2.09% to 6.10 premarket Sept. 21Reported Earnings • Aug 11Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.081 loss per share (down from US$0.052 loss in 2Q 2021). Revenue: US$9.61m (up 35% from 2Q 2021). Net loss: US$8.26m (loss widened 87% from 2Q 2021). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 4.0% growth forecast for the industry in the US.Seeking Alpha • Jul 12MaxCyte signs strategic platform with LG ChemMaxCyte (NASDAQ:MXCT) has announced the signing of a strategic platform license with LG Chem, aiming to create new value for its customers based on science. Under the terms, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue. “This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer.” said Doug Doerfler, President and CEO of MaxCyte.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.04 loss per share (up from US$0.088 loss in 1Q 2021). Revenue: US$11.6m (up 78% from 1Q 2021). Net loss: US$4.07m (loss narrowed 43% from 1Q 2021). Revenue exceeded analyst estimates by 36%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Over the next year, revenue is forecast to grow 17%, compared to a 6.5% growth forecast for the industry in the US.Recent Insider Transactions • Nov 25Independent Chairman of the Board recently bought US$222k worth of stockOn the 22nd of November, Richard Douglas bought around 20k shares on-market at roughly US$11.12 per share. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.Recent Insider Transactions • Nov 17Founder recently sold US$1.3m worth of stockOn the 12th of November, Douglas Doerfler sold around 100k shares on-market at roughly US$12.66 per share. This was the largest sale by an insider in the last 3 months. This was Douglas' only on-market trade for the last 12 months.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.032 loss per share (vs US$0.037 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$10.1m (up 33% from 3Q 2020). Net loss: US$2.68m (loss narrowed 6.8% from 3Q 2020).Reported Earnings • Sep 15Second quarter 2021 earnings released: US$0.052 loss per share (vs US$0.046 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$7.11m (up 38% from 2Q 2020). Net loss: US$4.42m (loss widened 47% from 2Q 2020).Seeking Alpha • Sep 06MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return ProfileMaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100% gross margins) are set to account for a larger percentage of revenues over time. MXCT offers an attractive risk/return profile for investors that want exposure to the cell and gene therapy area, but do not have the risk appetite to invest directly in the space.Breakeven Date Change • Aug 02Forecast breakeven pushed back to 2023The 3 analysts covering MaxCyte previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 34% per year to 2022. The company is expected to make a profit of US$5.40m in 2023. Average annual earnings growth of 78% is required to achieve expected profit on schedule.株主還元MXCTUS Life SciencesUS 市場7D16.3%9.4%1.6%1Y-49.2%16.1%28.5%株主還元を見る業界別リターン: MXCT過去 1 年間で16.1 % の収益を上げたUS Life Sciences業界を下回りました。リターン対市場: MXCTは、過去 1 年間で28.5 % のリターンを上げたUS市場を下回りました。価格変動Is MXCT's price volatile compared to industry and market?MXCT volatilityMXCT Average Weekly Movement11.2%Life Sciences Industry Average Movement8.5%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.0%安定した株価: MXCT 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: MXCTの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199891Maher Masoudwww.maxcyte.comライフサイエンス企業であるMaxCyte, Inc.は、細胞治療薬の発見、開発、商業化を米国内外で行っている。同社の製品は、小～中規模トランスフェクション用の静的エレクトロポレーション装置ExPERT ATx、タンパク質生産や医薬品開発、細胞ベースアッセイ用の治療標的発現用のフローエレクトロポレーション装置ExPERT STx、治療用途の大規模トランスフェクション用のフローエレクトロポレーション装置ExPERT GTx、超大容量細胞工学用のExPERT VLxで構成されている。また、細胞を処理しエレクトロポレーションするためのディスポーザブル・プロセッシング・アセンブリー（PA）、エレクトロポレーション・バッファー液やソフトウェア・プロトコルなどPAをサポートするアクセサリーも提供している。同社は、装置と技術のライセンス供与と販売、消耗品の販売を、細胞療法の開発者、創薬や開発、バイオ製造に使用する製薬会社やバイオテクノロジー企業に行う。マックスサイトは1998年に設立され、メリーランド州ロックビルに本社を置いている。もっと見るMaxCyte, Inc. 基礎のまとめMaxCyte の収益と売上を時価総額と比較するとどうか。MXCT 基礎統計学時価総額US$129.62m収益（TTM）-US$39.12m売上高(TTM)US$32.29m4.0xP/Sレシオ-3.3xPER（株価収益率MXCT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MXCT 損益計算書（TTM）収益US$32.29m売上原価US$6.29m売上総利益US$25.99mその他の費用US$65.11m収益-US$39.12m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.37グロス・マージン80.51%純利益率-121.16%有利子負債／自己資本比率0%MXCT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 11:24終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MaxCyte, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Mark MassaroBTIGMatthew HewittCraig-Hallum Capital Group LLCJulie SimmondsPanmure Liberum6 その他のアナリストを表示
お知らせ • May 14MaxCyte, Inc. Reiterates Earnings Revenue Guidance for the Full Year 2026MaxCyte, Inc. reiterated earnings revenue guidance for the full year 2026. For the full year, the company revenue expected to be $30 million to $32 million.
お知らせ • May 13MaxCyte, Inc. (NasdaqGS:MXCT) announces an Equity Buyback for $10 million worth of its shares.MaxCyte, Inc. (NasdaqGS:MXCT) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of its common stock. The program is valid for 1 year.
お知らせ • May 03MaxCyte, Inc., Annual General Meeting, Jun 17, 2026MaxCyte, Inc., Annual General Meeting, Jun 17, 2026. Location: 9713 key west avenue, suite 400, md 20850, rockville United States
お知らせ • Apr 30MaxCyte, Inc. to Report Q1, 2026 Results on May 12, 2026MaxCyte, Inc. announced that they will report Q1, 2026 results After-Market on May 12, 2026
お知らせ • Mar 25+ 1 more updateMaxCyte, Inc. Provides Earnings Guidance for the Full Year 2026MaxCyte, Inc. provided earnings guidance for the full year 2026. For the full year, the company expects revenue expected to be $30 million to $32 million.
お知らせ • Mar 23MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026MaxCyte, Inc. announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization, most recently serving as Vice President, Investor Relations at Agilent Technologies, where he worked closely with senior leadership to help shape and communicate the company’s narrative to analysts and investors. Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations. Mr. Ahuja holds an MBA in Finance from San Jose State University and a Bachelor of Commerce in Accounting from Delhi University.
お知らせ • May 14MaxCyte, Inc. Reiterates Earnings Revenue Guidance for the Full Year 2026MaxCyte, Inc. reiterated earnings revenue guidance for the full year 2026. For the full year, the company revenue expected to be $30 million to $32 million.
お知らせ • May 13MaxCyte, Inc. (NasdaqGS:MXCT) announces an Equity Buyback for $10 million worth of its shares.MaxCyte, Inc. (NasdaqGS:MXCT) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of its common stock. The program is valid for 1 year.
お知らせ • May 03MaxCyte, Inc., Annual General Meeting, Jun 17, 2026MaxCyte, Inc., Annual General Meeting, Jun 17, 2026. Location: 9713 key west avenue, suite 400, md 20850, rockville United States
お知らせ • Apr 30MaxCyte, Inc. to Report Q1, 2026 Results on May 12, 2026MaxCyte, Inc. announced that they will report Q1, 2026 results After-Market on May 12, 2026
お知らせ • Mar 25+ 1 more updateMaxCyte, Inc. Provides Earnings Guidance for the Full Year 2026MaxCyte, Inc. provided earnings guidance for the full year 2026. For the full year, the company expects revenue expected to be $30 million to $32 million.
お知らせ • Mar 23MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026MaxCyte, Inc. announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization, most recently serving as Vice President, Investor Relations at Agilent Technologies, where he worked closely with senior leadership to help shape and communicate the company’s narrative to analysts and investors. Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations. Mr. Ahuja holds an MBA in Finance from San Jose State University and a Bachelor of Commerce in Accounting from Delhi University.
お知らせ • Mar 21MaxCyte, Inc. Announces Notice of Non-Compliance with Nasdaq Minimum Bid Price RequirementOn March 16, 2026, MaxCyte, Inc. received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Select Market, and the Company's common stock will continue to trade on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until September 14, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive trading days prior September 14, 2026. If the Company does not regain compliance by September 14, 2026, the Company may be eligible for an additional 180 calendar day compliance period if it applies to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period. As part of its review process, Nasdaq will make a determination as to whether it believes the Company will be able to cure this deficiency. If Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company's common stock will be subject to delisting. Upon receipt of such notice, the Company would have the right to appeal any determination to delist its common stock, and the common stock would remain listed on the Nasdaq Global Select Market until completion of the appeal process. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other applicable Nasdaq listing rules.
お知らせ • Feb 24+ 1 more updateMaxCyte, Inc. Unveils Expert DTx, A 96-Well Electroporation Platform to Accelerate DiscoveryMaxCyte, Inc. announced the launch of ExPERT DTx, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes. ExPERT DTx streamlines workflows by processing up to 96 samples in a single, three-minute run. The platform's R-50x96 well processing assembly provides one of the most cost-effective solutions for 96-well electroporation on the market, allowing 12 detachable 8-well strips to be processed in parallel with unique parameters for different cell and cargo combinations. This ensures consistent well-to-well performance that effectively eliminates transfection as an experimental variable, while maximizing flexibility and reducing laboratory waste. It has been validated in a range of applications - from cell and gene therapy development to protein production - and enables the transfer of optimized processes to other ExPERT instruments, simplifying scale-up from discovery into cGMP-compliant manufacturing without the need to reoptimize workflows. One of the defining features of the platform is its efficient and user-friendly software package. The DTx Software controls and monitors the instrument, while the DTx Designer software introduces a distinct advantage over current options on the market, enabling users to design their experiments remotely, then upload the workflow when the system is available for use. This maximizes uptime, and is especially beneficial to labs running multiple, back-to-back experiments.
お知らせ • Nov 13MaxCyte, Inc. Announces Planned CFO Transition in 2026MaxCyte, Inc. announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working closely to ensure a smooth and orderly transition, and he will remain Chief Financial Officer until a successor has been appointed. The Company has initiated a structured search process to identify Mr. Swirsky’s successor. Following the transition period, Mr. Swirsky will continue in an advisory capacity to support strategic initiatives and ensure continuity.
お知らせ • Nov 05MaxCyte, Inc. Reiterates Revenue Guidance for the Full Year 2025MaxCyte, Inc. reiterated revenue guidance for the full year 2025. The company core revenue is expected to be flat to a 10% decline compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
お知らせ • Oct 08MaxCyte, Inc. to Report Q3, 2025 Results on Nov 05, 2025MaxCyte, Inc. announced that they will report Q3, 2025 results After-Market on Nov 05, 2025
お知らせ • Sep 23+ 1 more updateMaxCyte, Inc. Reiterates Earnings Guidance for the Year 2025MaxCyte, Inc. reiterated earnings guidance for the year 2025. Consistent with its previously issued outlook, The company is reiterating that 2025 core revenue is expected to be flat to down approximately 10% compared to 2024.
お知らせ • Aug 07MaxCyte, Inc. Lowers Earnings Guidance for the Year 2025MaxCyte, Inc. lowered earnings guidance for the year 2025. For the year, Core revenue is expected to be flat to a 10% decline compared to 2024, inclusive of revenue from SeQure Dx.
お知らせ • Jul 09MaxCyte, Inc. to Report Q2, 2025 Results on Aug 06, 2025MaxCyte, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025
お知らせ • Jun 25MaxCyte Shareholders Approves Common Stock Cancelation DateMaxCyte, Inc. provided further update with regards to the cancellation of admission of the Company's common stock ("Common Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at the Annual General Meeting held on 18 June 2025. Shareholders are reminded that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025. Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.
お知らせ • May 08MaxCyte, Inc. Reiterates Revenue Guidance for the Year 2025MaxCyte, Inc. reiterated revenue guidance for the year 2025. For the year, the company reiterates core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
お知らせ • Apr 17MaxCyte, Inc., Annual General Meeting, Jun 18, 2025MaxCyte, Inc., Annual General Meeting, Jun 18, 2025. Location: 9713 key west avenue, suite 400, rockville, 20850, maryland United States
お知らせ • Apr 10MaxCyte, Inc. to Report Q1, 2025 Results on May 07, 2025MaxCyte, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
New Risk • Mar 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$46k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Significant insider selling over the past 3 months (US$46k sold).
Seeking Alpha • Mar 15MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share PriceSummary MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by the strong growth of the global cell therapy market. Geopolitical tensions and a slowdown in the economy have hurt the share price, not problems in the company's business operations. MaxCyte's robust financial situation and strategic growth initiatives make its current share price attractive relative to its potential upside. Read the full article on Seeking Alpha
Reported Earnings • Mar 12Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: US$0.39 loss per share (further deteriorated from US$0.37 loss in FY 2023). Revenue: US$38.6m (down 6.4% from FY 2023). Net loss: US$41.1m (loss widened 8.3% from FY 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.1%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 12MaxCyte, Inc. Provides Revenue Guidance for the Year 2025MaxCyte, Inc. provided revenue guidance for the year 2025. For the period, the company expects core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
Price Target Changed • Mar 09Price target decreased by 7.1% to US$8.67Down from US$9.33, the current price target is an average from 2 analysts. New target price is 147% above last closing price of US$3.51. Stock is down 11% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.37 last year.
Buy Or Sell Opportunity • Feb 12Now 24% undervaluedOver the last 90 days, the stock has risen 17% to US$4.14. The fair value is estimated to be US$5.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.
お知らせ • Feb 07MaxCyte, Inc. to Report Q4, 2024 Results on Mar 11, 2025MaxCyte, Inc. announced that they will report Q4, 2024 results at 4:30 PM, GMT Standard Time on Mar 11, 2025
お知らせ • Jan 30MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million.MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million on January 30, 2025. Maxcyte paid a total consideration of $4.5 million at closing in cash for the entire issued share capital of SeQure DX on a cash free, debt free basis using Maxcyte’s existing cash resources and an additional amount of $2.5 million to be paid in contingent consideration if the SeQure exceeds certain revenue targets. For the period ending December 31, 2024, SeQure Dx, Inc. reported total revenue of $1.7 million and net loss of $6.5 million and total assets of $0.7 million. MaxCyte, Inc. (AIM:MXCT) completed the acquisition of SeQure Dx, Inc. on January 30, 2025.
Buy Or Sell Opportunity • Jan 24Now 21% undervaluedOver the last 90 days, the stock has risen 31% to US$4.66. The fair value is estimated to be US$5.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.
お知らせ • Dec 23MaxCyte, Inc. Announces Retirement of Board Member Art MandellMaxCyte, Inc. announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors. During Mr. Mandell’s tenure, MaxCyte has achieved significant milestones including its initial public offering on the UK AIM exchange and US Nasdaq Listing, the launch of its flagship ExPERT™ platform, signing 29 Strategic Platform Licenses with cell and gene therapy biotech companies and supporting the industry’s first, FDA-approved, CRISPR edited non-viral cell therapy.
Price Target Changed • Dec 10Price target decreased by 7.1% to US$8.67Down from US$9.33, the current price target is an average from 2 analysts. New target price is 108% above last closing price of US$4.17. Stock is down 17% over the past year. The company is forecast to post a net loss per share of US$0.41 next year compared to a net loss per share of US$0.37 last year.
お知らせ • Dec 10MaxCyte, Inc. Raises Revenue Guidance for 2024MaxCyte, Inc. raised Revenue guidance for 2024. For the period, the company expects core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.
Reported Earnings • Nov 07Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.11 loss per share (further deteriorated from US$0.11 loss in 3Q 2023). Revenue: US$8.16m (up 2.0% from 3Q 2023). Net loss: US$11.6m (loss widened 2.7% from 3Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 07MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024MaxCyte, Inc. updated revenue guidance for the full year 2024. For the period, Company expects core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY.
お知らせ • Oct 15MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive DirectorMaxCyte, Inc. announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. Ms. Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as Chief Executive Officer of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene modified therapy. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc., Chief Executive Officer/General Manager of General Electric Healthcare's Cell Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy company. Currently, Ms. Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics, Certara, DermTech, Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines. Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business. Cynthia Collins, was previously appointed as an independent director to the Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the District of Delaware approved the sale of a substantial amount of DermTech Inc.'s assets through a court-supervised auction.
お知らせ • Oct 11MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024MaxCyte, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
お知らせ • Oct 10MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial OfficerMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company’s market impact in Cell and Gene Therapy. Prior to his role as Chief Commercial Officer, Mr. Soleymannezhad was the Executive Vice President of Bioprocessing, where he led global product development and marketing strategy for MaxCyte’s bioprocessing business. Mr. Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to Executive Vice President of Bioprocessing at MaxCyte, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience and oversaw a team of 140 employees across four global manufacturing, development, and commercial sites. Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing-Americas at Tosoh and served on the board of Semba Biosciences.
Reported Earnings • Aug 07Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.09 loss per share (improved from US$0.10 loss in 2Q 2023). Revenue: US$10.4m (up 15% from 2Q 2023). Net loss: US$9.38m (loss narrowed 11% from 2Q 2023). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 07MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. reaffirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance. The company continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM.
New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$42m net loss in 2 years). Share price has been volatile over the past 3 months (9.8% average weekly change).
お知らせ • Jul 10MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024MaxCyte, Inc. announced that they will report Q2, 2024 results at 4:30 PM, GMT Standard Time on Aug 06, 2024
お知らせ • Jul 03MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth IndexMaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index
Recent Insider Transactions • Jun 13President recently bought US$489k worth of stockOn the 10th of June, Maher Masoud bought around 100k shares on-market at roughly US$4.89 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Maher's only on-market trade for the last 12 months.
お知らせ • May 09Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024MaxCyte, Inc. affirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and is increasing SPL Program-related revenue guidance. MaxCyte continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $5 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY™.
Price Target Changed • May 08Price target decreased by 7.1% to US$8.67Down from US$9.33, the current price target is an average from 2 analysts. New target price is 87% above last closing price of US$4.64. Stock is down 0.2% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.37 last year.
お知らせ • Apr 28MaxCyte, Inc., Annual General Meeting, Jun 11, 2024MaxCyte, Inc., Annual General Meeting, Jun 11, 2024, at 11:00 US Eastern Standard Time. Location: 9713 Key West Avenue, Suite 400 Rockville Maryland United States Agenda: To elect the Board’s three nominees as identified in the accompanying Proxy Statement as Class III directors: Will Brooke, John Johnston, and Richard Douglas; to approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the shares of the Company’s common stock issuable thereunder by 2,300,000 shares; to ratify the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting.
お知らせ • Apr 11MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024MaxCyte, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
お知らせ • Mar 14MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024MaxCyte, Inc. reiterated earnings guidance for the year 2024. Management is reiterating 2024 revenue guidance for core business revenue and SPL Program-related revenue. Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million. Outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM and reflects a difficult year-over-year comparison from a client milestone recognized in 2023 that was initially expected in 2024.
Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.37 loss per share (further deteriorated from US$0.23 loss in FY 2022). Revenue: US$41.3m (down 6.7% from FY 2022). Net loss: US$37.9m (loss widened 61% from FY 2022). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 07MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024MaxCyte, Inc. provided revenue guidance for the fiscal year 2023 and 2024. For the year 2023, Company re-affirms total revenue to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022. Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.For the Year 2024, Company expects Core revenue to be flat to 5% growth compared to 2023.
お知らせ • Feb 10MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024MaxCyte, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024
お知らせ • Jan 27MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific OfficerMaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.’s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company’s Scientific Advisory Board.
お知らせ • Jan 09MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023MaxCyte, Inc. provided preliminary financial guidance for the fourth quarter and full year ended December 31, 2023. Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.
お知らせ • Dec 12MaxCyte, Inc. Provides Revenue Guidance Update for 2023MaxCyte, Inc. is reiterating 2023 expected core business revenue of $28 million- $30 million, and the company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million. Core business revenue consists of sales and leases of instrument and disposables to cell therapy and drug discovery customers and excludes any milestone revenues under SPL programs.
New Risk • Nov 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$42m net loss in 2 years).
お知らせ • Nov 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the period, the company expects total revenue to be approximately $34 million - 36 million.
Reported Earnings • Nov 10Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.063 loss in 3Q 2022). Revenue: US$8.00m (down 25% from 3Q 2022). Net loss: US$11.3m (loss widened 75% from 3Q 2022). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 7.8%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Life Sciences industry in the US.
お知らせ • Oct 07MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023MaxCyte, Inc. provided revenue guidance for the third quarter and full year of 2023. Total revenue of $7.8 million to $8.0 million in the third quarter of 2023, a decrease of 25% to 27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector.For the full year, the company’s total revenue now expected to be approximately $34 million to $36 million.
New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.6% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$38m net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change).
お知らせ • Oct 05MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023MaxCyte, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
Price Target Changed • Oct 05Price target decreased by 9.5% to US$9.50Down from US$10.50, the current price target is an average from 2 analysts. New target price is 191% above last closing price of US$3.27. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.23 last year.
お知らせ • Sep 07Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingMaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. Mr. Soleymannezhad will lead global product development and marketing strategy for MaxCyte's bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and manufacturing using transient expression to produce complex proteins, vaccines and biologics at scale. Mr. Soleymannezhad brings almost 20 years of technical, sales and marketing expertise in biomanufacturing, bioprocessing and bioanalysis to his new role. Most recently, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience overseeing a team of 140 employees across four global manufacturing, development, and commercial sites. During his tenure at Tosoh, Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing Americas and served on the board of Semba Biosciences. Mr. Soleymannezhad received a Master of Business Administration in finance from Jones Graduate School of Business at Rice University in Texas after completing his Master and Bachelor of Chemical Engineering at University of Western Ontario's Faculty of Engineering in Canada.
New Risk • Aug 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years).
Price Target Changed • Aug 10Price target decreased by 9.5% to US$9.50Down from US$10.50, the current price target is an average from 2 analysts. New target price is 143% above last closing price of US$3.91. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$0.35 next year compared to a net loss per share of US$0.23 last year.
お知らせ • Aug 10MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects core revenue to be comparable to 2022 and Strategic Platform License program-related revenue expectations remain unchanged at approximately $6 million.
お知らせ • Jul 14MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023MaxCyte, Inc. announced that they will report Q2, 2023 results at 4:30 PM, GMT Standard Time on Aug 09, 2023
Reported Earnings • May 12First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.04 loss in 1Q 2022). Revenue: US$8.58m (down 26% from 1Q 2022). Net loss: US$10.9m (loss widened 168% from 1Q 2022). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Life Sciences industry in the US.
お知らせ • May 11MaxCyte, Inc. Provides Revenue Guidance for the Year 2023MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects total revenue to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and Strategic Platform License (“SPL”) program-related revenue expectations remaining the same at approximately $6 million for the year.
Board Change • Apr 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Member of Scientific Advisory Board Marcela Maus was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Apr 01Key Executive recently bought US$345k worth of stockOn the 29th of March, Richard Douglas bought around 80k shares on-market at roughly US$4.32 per share. This transaction increased Richard's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.
Reported Earnings • Mar 16Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)Full year 2022 results: US$0.23 loss per share (further deteriorated from US$0.21 loss in FY 2021). Revenue: US$44.3m (up 31% from FY 2021). Net loss: US$23.6m (loss widened 24% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US.
お知らせ • Feb 02MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023MaxCyte, Inc. announced that they will report Q4, 2022 results at 4:30 PM, GMT Standard Time on Mar 15, 2023
Price Target Changed • Jan 08Price target decreased to US$11.67Down from US$13.67, the current price target is an average from 2 analysts. New target price is 123% above last closing price of US$5.23. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$0.25 next year compared to a net loss per share of US$0.21 last year.
Reported Earnings • Nov 11Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.063 loss per share (further deteriorated from US$0.032 loss in 3Q 2021). Revenue: US$10.6m (up 5.0% from 3Q 2021). Net loss: US$6.43m (loss widened 140% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.
Seeking Alpha • Sep 21MaxCyte expands capacity by relocating to new HQ in MarylandMaxCyte (NASDAQ:MXCT) said it relocated its headquarters to Key West Avenue in Rockville, Maryland, within Maryland's I-270 Biotech Corridor. The new 67K square-foot facility increases MaxCyte's in-house manufacturing capacity and research and process development lab space, the company said in a Sept. 21 press release. MXCT -2.09% to 6.10 premarket Sept. 21
Reported Earnings • Aug 11Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.081 loss per share (down from US$0.052 loss in 2Q 2021). Revenue: US$9.61m (up 35% from 2Q 2021). Net loss: US$8.26m (loss widened 87% from 2Q 2021). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 4.0% growth forecast for the industry in the US.
Seeking Alpha • Jul 12MaxCyte signs strategic platform with LG ChemMaxCyte (NASDAQ:MXCT) has announced the signing of a strategic platform license with LG Chem, aiming to create new value for its customers based on science. Under the terms, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue. “This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer.” said Doug Doerfler, President and CEO of MaxCyte.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.04 loss per share (up from US$0.088 loss in 1Q 2021). Revenue: US$11.6m (up 78% from 1Q 2021). Net loss: US$4.07m (loss narrowed 43% from 1Q 2021). Revenue exceeded analyst estimates by 36%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Over the next year, revenue is forecast to grow 17%, compared to a 6.5% growth forecast for the industry in the US.
Recent Insider Transactions • Nov 25Independent Chairman of the Board recently bought US$222k worth of stockOn the 22nd of November, Richard Douglas bought around 20k shares on-market at roughly US$11.12 per share. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.
Recent Insider Transactions • Nov 17Founder recently sold US$1.3m worth of stockOn the 12th of November, Douglas Doerfler sold around 100k shares on-market at roughly US$12.66 per share. This was the largest sale by an insider in the last 3 months. This was Douglas' only on-market trade for the last 12 months.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.032 loss per share (vs US$0.037 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$10.1m (up 33% from 3Q 2020). Net loss: US$2.68m (loss narrowed 6.8% from 3Q 2020).
Reported Earnings • Sep 15Second quarter 2021 earnings released: US$0.052 loss per share (vs US$0.046 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$7.11m (up 38% from 2Q 2020). Net loss: US$4.42m (loss widened 47% from 2Q 2020).
Seeking Alpha • Sep 06MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return ProfileMaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100% gross margins) are set to account for a larger percentage of revenues over time. MXCT offers an attractive risk/return profile for investors that want exposure to the cell and gene therapy area, but do not have the risk appetite to invest directly in the space.
Breakeven Date Change • Aug 02Forecast breakeven pushed back to 2023The 3 analysts covering MaxCyte previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 34% per year to 2022. The company is expected to make a profit of US$5.40m in 2023. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
